Quick Summary
- Eli Lilly is acquiring Centessa Pharmaceuticals for up to $7.8 billion to aggressively expand its footprint in the sleep medicine and neuroscience markets.
- The deal centers on cleminorexton (ORX750), a potential “best-in-class” orexin agonist designed to treat narcolepsy and idiopathic hypersomnia by targeting the brain’s wakefulness switch.
- Lilly is leveraging record profits from its metabolic health franchise to pivot toward high-growth neurological therapies, with the deal expected to close in the third quarter of 2026.
Lilly acquires Centessa Pharmaceuticals in a strategic move that marks the pharmaceutical giant’s major entry into the sleep medicine landscape. Announced on March 31, 2026, the acquisition centers on Centessa’s pioneering orexin receptor 2 (OX2R) agonist pipeline, which is poised to redefine how patients manage excessive daytime sleepiness and other neurological conditions.
The transaction is valued at approximately $6.3 billion in upfront cash, or $38.00 per share, representing a 40.5% premium to Centessa’s recent average trading price. Additionally, Centessa shareholders may receive up to $1.5 billion via contingent value rights (CVRs), bringing the total potential deal value to **$7.8 billion**.
Why Lilly Acquires Centessa Pharmaceuticals for Orexin Science?
The cornerstone of this acquisition is cleminorexton (formerly ORX750), an investigational oral OX2R agonist. Cleminorexton has already demonstrated “best-in-class” potential in Phase 2a clinical trials for Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia. By targeting the orexin system the brain’s master switch for the sleep-wake cycle, Lilly aims to provide a mechanistically targeted alternative to traditional stimulants.
Strategic Expansion of Lilly’s Neuroscience Portfolio
This deal follows a series of other high-profile acquisitions by Lilly in 2026, including deals for Orna Therapeutics and Ventyx Bio, highlighting a clear trend of reinvesting capital from blockbuster drugs like Mounjaro and Zepbound into high-growth therapeutic areas.
Read More: Lilly to Bolster Immunology Pipeline with $1.2 Billion Acquisition of Ventyx Biosciences
Financial Terms and Path to Closing
The boards of both companies have unanimously approved the merger. To ensure a smooth transition, major Centessa shareholders, including Medicxi and General Atlantic, have signed voting support agreements.
Key Financial Highlights:
- Upfront Payment: $38.00 per share in cash.
- CVR Milestones: Up to $9.00 per share tied to FDA approvals for cleminorexton or ORX142 in narcolepsy and idiopathic hypersomnia.
- Expected Close: Third quarter of 2026.
According to the official Centessa Pharmaceuticals investor relations portal, the company will leverage Lilly’s global clinical, regulatory, and commercial infrastructure to accelerate its OX2R pipeline across multiple indications, including neurodegenerative and neuropsychiatric disorders.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
A New Era for Patients with Sleep-Wake Disorders
For decades, treatments for narcolepsy and excessive daytime sleepiness (EDS) have focused on symptom management. The move where Lilly acquires Centessa Pharmaceuticals signals a shift toward precision medicine in neurology. Orexin agonists represent a “biological fix” for the deficiency that causes narcolepsy, potentially offering patients a degree of wakefulness and cognitive clarity previously thought unattainable.
